Navigation Links
MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
Date:8/17/2010

SAN DIEGO, Aug. 17 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP). Under the SNAP procedures, both initial and follow-on grant requests are submitted and evaluated as one request.  The initial grant award of $150,000 goes to support the manufacture and testing of the company's sarcoma vaccine currently in clinical testing. The follow-on grant application, for more than $1.5 million, can be funded under fast-track procedures following normal NCI reporting and review procedures.

"While the initial grant is modest, it is the critical gateway to substantially more funding that will offset patient and investigator expenses at the 12 investigative sites we have recruited for the Phase 2 clinical trial that is just getting underway," said David Hansen, CEO of MabVax.  He added that "the SNAP program allows the company to submit a grant request that encompasses substantially more of the research project and potentially allows for more rapid funding of the entire grant request."

The sarcoma vaccine grant is intended to support the Phase II clinical trial that will enroll 134 metastatic sarcoma patients in a randomized, multicenter, double-blind study of the trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent cancer.  In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers.  Prognosis remains poor, with more than 5,200 patients in the US dying of disease each year.  As in other malignancies, disease recurrence and metastasis are common in sarcoma.  Despite undergoing potentially curative surgical resection or combination therapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  

The vaccine is designed to instruct the patient's immune system to make antibodies against the three ganglioside antigens present on the surface of sarcoma cells. The antibodies will then seek out and eliminate residual circulating cancer cells and micrometastases. The vaccine was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development work was completed in 2009.  MabVax exclusively licensed the sarcoma vaccine, along with additional vaccines targeting other neuroectodermal and epithelial cancers, from MSKCC in 2008.  

Patients who would like additional information are directed to the website clinicaltrials.gov where more details can be found.

About MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. The company was formed to exploit key aspects of the work of Dr. Philip Livingston and colleagues at MSKCC who have developed cancer vaccines against gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. The company believes that passively administered or vaccine induced antibodies against selected tumor cell surface antigens are ideally suited for eradication of free tumor cells and micrometastases that remain after initial treatment and cause cancer recurrence.  The company plans to commercially develop vaccines against several different types of cancer over the coming years.  Concurrently, MabVax is creating a pipeline of monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The company is based in San Diego, CA. MabVax has closed two Series A rounds of venture financing in February 2008 and August of 2009.  


'/>"/>
SOURCE MabVax Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
2. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
3. Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea
4. CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO
5. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Talecris Biotherapeutics to Report Second Quarter 2010 Financial Results
8. Talecris Biotherapeutics Announces Premerger HSR Filing
9. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
10. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
11. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Diego, CA (PRWEB) , ... April 29, 2016 , ... ... Foundation (NSCF) to support the development of a patient-specific stem cell therapy for the ... in the lab of Dr. Jeanne Loring at The Scripps Research Institute in San ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut Innovations ... growing companies, today announced the launch of VentureClash , a $5 million ... , “VentureClash looks to attract the best early-stage companies here in Connecticut, ...
(Date:4/27/2016)... ... ... Shimadzu Scientific Instruments (SSI) will be showcasing a broad ... Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, moisture, ... booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, peak ...
(Date:4/27/2016)... ... April 27, 2016 , ... The ... announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined ... of the founding commercial leaders responsible for the commercialization of multiple orphan drug ...
Breaking Biology Technology:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):